Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations
Open accessThe DOI matches its Crossref record.
Abstract
Erythropoietic agents have transformed the management of renal anaemia. Two forms of recombinant human erythropoietin (rHuEPO) have been available since the early 1990s, and more recently, a second-generation erythropoietic agent, darbepoetin alfa, has been granted a licence for treating this condition. The endogenous erythropoietin molecule may contain anything from 4 to 14 sialic acid residues. The various isoforms have different biological potencies in vivo owing to their different metabolic clearance rates. However, there is a continuing debate about those organs potentially involved in the metabolism of the erythropoietin molecule; the kidneys, liver, and bone marrow have all been suggested as possible participants. Darbepoetin alfa contains two extra N-linked glycosylation consensus sequences increasing the potential maximum number of sialic acid residues from 14 up to 22. In vitro, the affinity of darbepoetin alfa for the erythropoietin receptor is less than for the natural ligand, but this is more than compensated for by the increased potency in vivo. One of the most important factors determining the biological activity of erythropoiesis-stimulating agents is the length of time that the serum concentration of the protein remains above the threshold necessary for erythropoiesis. The pharmacokinetic profile of darbepoetin alfa is distinct from that of rHuEPO, the major difference being the much longer elimination half-life and slower clearance in vivo of darbepoetin alfa leading to prolonged erythropoietic activity. Stimulation of erythropoiesis depends both on an ambient circulating level of erythropoietin and on the mechanisms governing the interaction of the hormone with its receptor. Our knowledge regarding the latter is limited and it is difficult to predict the optimum frequency of administration for an erythropoietic agent. In general, rHuEPO is given two or three times weekly. A small number of studies have supported the once-weekly use of rHuEPO. All clinical trials so far conducted on darbepoetin alfa have demonstrated success with once-weekly and once every other week dosing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glycosylation of Therapeutic Proteins: An Effective Strategy to Optimize Efficacy
Solá, R. J., & Griebenow, K. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 440
Characterizing biological products and assessing comparability following manufacturing changes
Chirino, A. J., & Mire-Sluis, A. (2004) · Nature Biotechnology · doi:10.1038/nbt1030 · Cited by 364
A mathematical model of N-linked glycosylation
Krambeck, F. J., & Betenbaugh, M. J. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20645 · Cited by 171
Expanding the glycoengineering toolbox: the rise of bacterial N-linked protein glycosylation
Baker, J. L., Çelik, E., & DeLisa, M. P. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.03.003 · Cited by 67
Glycans‐by‐design: Engineering bacteria for the biosynthesis of complex glycans and glycoconjugates
Merritt, J. H., Ollis, A. A., Fisher, A. C., & DeLisa, M. P. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24885 · Cited by 51
Metadata
- Authors
- Macdougall, I. C.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-05-01
- Volume
- 17
- Issue
- 90005
- Pages
- 66-70
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2143201063
- Cited by
- 118
- References
- 0
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. https://app.cochat.ai/papers/10.1093/ndt/17.suppl_5.66
- The paper
- Macdougall, I. C. (2002). Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/17.suppl_5.66
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.